AbbVie Inc. – NYSE:ABBV
AbbVie stock price today
$206.696
+28.68
+16.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
AbbVie stock price monthly change
+4.54%
month
AbbVie stock price quarterly change
+4.54%
quarter
AbbVie stock price yearly change
+14.93%
year
AbbVie key metrics
Market Cap | 309.79B |
Enterprise value | 378.39B |
P/E | 61.47 |
EV/Sales | 6.81 |
EV/EBITDA | 15.60 |
Price/Sales | 5.66 |
Price/Book | 52.20 |
PEG ratio | 0.72 |
EPS | 3.37 |
Revenue | 54.40B |
EBITDA | 18.46B |
Income | 5.99B |
Revenue Q/Q | 0.69% |
Revenue Y/Y | -4.12% |
Profit margin | 9.22% |
Oper. margin | 24.89% |
Gross margin | 76.85% |
EBIT margin | 24.89% |
EBITDA margin | 33.93% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAbbVie stock price history
AbbVie stock forecast
AbbVie financial statements
Average Price Target
$211.29
Potential upside: 2.22%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 13.86B | 2.02B | 14.6% |
|---|---|---|---|
| Sep 2023 | 13.92B | 1.77B | 12.77% |
| Dec 2023 | 14.30B | 822M | 5.75% |
| Mar 2024 | 12.31B | 1.36B | 11.12% |
Paying a dividend greater than earnings.
3.48%
Yield TTM
| Payout ratio | 212.79% |
|---|
| 2019 | 4.85% |
|---|---|
| 2020 | 4.32% |
| 2021 | 3.86% |
| 2022 | 3.51% |
| 2023 | 3.85% |
| Jun 2023 | 135367000000 | 122.46B | 90.47% |
|---|---|---|---|
| Sep 2023 | 136221000000 | 124.09B | 91.1% |
| Dec 2023 | 134711000000 | 124.31B | 92.28% |
| Mar 2024 | 148874000000 | 140.82B | 94.59% |
| Jun 2023 | 6.31B | -341M | -3.92B |
|---|---|---|---|
| Sep 2023 | 7.57B | -369M | -2.66B |
| Dec 2023 | 4.75B | -800M | -4.44B |
| Mar 2024 | 4.04B | -9.58B | 10.81B |
AbbVie alternative data
What is mobile apps rank?
Complete – Medication Tracker
| Platform: | Android |
| Store: | Google Play  |
| Type: | Free |
| Market: | United States |
Category:
| Aug 2023 | 195 |
|---|---|
| Sep 2023 | 188 |
| Feb 2024 | 184 |
| Mar 2024 | 179 |
| Apr 2024 | 168 |
| May 2024 | 176 |
| Jun 2024 | 183 |
| Jul 2024 | 190 |
| Aug 2024 | 153 |
| Sep 2024 | 127 |
| Oct 2024 | 140 |
| Nov 2024 | 132 |
| Dec 2024 | 157 |
AbbVie Social Media Accounts
What are followers?
+0.74%
month
+2.60%
quarter
| Sep 2023 | 40401 |
|---|
+1.64%
month
| May 2025 | 41526 |
|---|---|
| Jul 2025 | 42635 |
| Aug 2025 | 43336 |
AbbVie
| 14 May 2023 | 35 |
|---|---|
| 21 May 2023 | 35 |
| 28 May 2023 | 33 |
| 4 Jun 2023 | 36 |
| 11 Jun 2023 | 34 |
| 18 Jun 2023 | 36 |
| 25 Jun 2023 | 34 |
| 2 Jul 2023 | 34 |
| 9 Jul 2023 | 35 |
| 16 Jul 2023 | 32 |
| 23 Jul 2023 | 35 |
| 30 Jul 2023 | 36 |
| 6 Aug 2023 | 36 |
| 13 Aug 2023 | 38 |
| 20 Aug 2023 | 46 |
| 27 Aug 2023 | 36 |
| 3 Sep 2023 | 37 |
| 10 Sep 2023 | 37 |
| 17 Sep 2023 | 38 |
| 24 Sep 2023 | 23 |
AbbVie Immunology Products
| 11 Jun 2023 | 0 | 8 | 60 |
|---|---|---|---|
| 18 Jun 2023 | 0 | 5 | 71 |
| 25 Jun 2023 | 0 | 6 | 70 |
| 2 Jul 2023 | 0 | 7 | 66 |
| 9 Jul 2023 | 0 | 8 | 65 |
| 16 Jul 2023 | 0 | 7 | 71 |
| 23 Jul 2023 | 0 | 7 | 72 |
| 30 Jul 2023 | 0 | 8 | 71 |
| 6 Aug 2023 | 0 | 8 | 64 |
| 13 Aug 2023 | 0 | 7 | 72 |
| 20 Aug 2023 | 0 | 6 | 71 |
| 27 Aug 2023 | 0 | 9 | 62 |
| 3 Sep 2023 | 0 | 8 | 59 |
| 10 Sep 2023 | 0 | 9 | 66 |
| 17 Sep 2023 | 0 | 8 | 66 |
| 24 Sep 2023 | 0 | 7 | 62 |
| 1 Oct 2023 | 0 | 10 | 68 |
| 8 Oct 2023 | 0 | 8 | 71 |
| 15 Oct 2023 | 0 | 7 | 74 |
| 22 Oct 2023 | 0 | 7 | 56 |
AbbVie Virology and Oncology Products
| 21 May 2023 | 27 | 11 | 4 | 27 |
|---|---|---|---|---|
| 28 May 2023 | 15 | 8 | 0 | 33 |
| 4 Jun 2023 | 20 | 10 | 2 | 29 |
| 11 Jun 2023 | 14 | 7 | 2 | 27 |
| 18 Jun 2023 | 16 | 12 | 0 | 32 |
| 25 Jun 2023 | 20 | 10 | 0 | 38 |
| 2 Jul 2023 | 11 | 5 | 3 | 25 |
| 9 Jul 2023 | 13 | 10 | 0 | 23 |
| 16 Jul 2023 | 16 | 12 | 3 | 29 |
| 23 Jul 2023 | 20 | 9 | 4 | 32 |
| 30 Jul 2023 | 21 | 9 | 0 | 28 |
| 6 Aug 2023 | 13 | 12 | 0 | 27 |
| 13 Aug 2023 | 15 | 6 | 1 | 25 |
| 20 Aug 2023 | 19 | 6 | 2 | 31 |
| 27 Aug 2023 | 18 | 16 | 0 | 20 |
| 3 Sep 2023 | 11 | 8 | 0 | 16 |
| 10 Sep 2023 | 18 | 10 | 0 | 21 |
| 17 Sep 2023 | 18 | 6 | 3 | 27 |
| 24 Sep 2023 | 15 | 13 | 0 | 17 |
| 1 Oct 2023 | 11 | 7 | 2 | 21 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Sep 2023 | 1,005 |
|---|---|
| Oct 2023 | 1,014 |
| Nov 2023 | 1,043 |
| Dec 2023 | 1,004 |
| Jan 2024 | 986 |
| Feb 2024 | 1,084 |
| Apr 2024 | 1,222 |
| May 2024 | 1,413 |
| Jun 2024 | 1,286 |
| Jul 2024 | 1,217 |
| Sep 2023 | 50,000 |
|---|---|
| Oct 2023 | 50,000 |
| Nov 2023 | 50,000 |
| Dec 2023 | 50,000 |
| Jan 2024 | 50,000 |
| Feb 2024 | 50,000 |
| Mar 2024 | 50,000 |
| Apr 2024 | 50,000 |
| May 2024 | 50,000 |
| Jun 2024 | 50,000 |
| Jul 2024 | 50,000 |
AbbVie other data
66.51%
-0.32%
of ABBV is owned by hedge funds
2.93K
+33
1.18B
-5.69M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 303293 |
| Mar 2024 | 0 | 155711 |
| Jul 2024 | 0 | 282845 |
| Aug 2024 | 0 | 66500 |
| Dec 2024 | 0 | 1800 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BUCKBEE KEVIN K officer: SVP, CONTROLLER | Option (Right to buy) | 1,800 | $93.5 | $168,300 | ||
Option | BUCKBEE KEVIN K officer: SVP, CONTROLLER | Common Stock, $0.01 par value | 1,800 | $93.5 | $168,300 | ||
Sale | BUCKBEE KEVIN K officer: SVP, CONTROLLER | Common Stock, $0.01 par value | 1,800 | $172.24 | $310,032 | ||
Sale | GONZALEZ RICHARD A director, officer.. | Common Stock, $0.01 par value | 66,500 | $186.52 | $12,403,580 | ||
Option | GONZALEZ RICHARD A director, officer.. | Common Stock, $0.01 par value | 76,377 | $93.5 | $7,141,250 | ||
Option | GONZALEZ RICHARD A director, officer.. | Common Stock, $0.01 par value | 119,418 | $79.02 | $9,436,410 | ||
Option | GONZALEZ RICHARD A director, officer.. | Common Stock, $0.01 par value | 87,050 | $61.36 | $5,341,388 | ||
Sale | GONZALEZ RICHARD A director, officer.. | Common Stock, $0.01 par value | 282,845 | $175 | $49,497,875 | ||
Option | GONZALEZ RICHARD A director, officer.. | Option (Right To Buy) | 76,377 | $93.5 | $7,141,250 | ||
Option | GONZALEZ RICHARD A director, officer.. | Option (Right To Buy) | 119,418 | $79.02 | $9,436,410 |
| Patent |
|---|
Application Filling date: 10 May 2022 Issue date: 8 Sep 2022 |
Application PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- -TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Filling date: 9 Feb 2022 Issue date: 8 Sep 2022 |
Application Filling date: 28 Apr 2022 Issue date: 1 Sep 2022 |
Application Filling date: 10 May 2022 Issue date: 25 Aug 2022 |
Application PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- -TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Filling date: 2 May 2022 Issue date: 25 Aug 2022 |
Application Filling date: 30 Mar 2022 Issue date: 25 Aug 2022 |
Application Filling date: 29 Nov 2018 Issue date: 25 Aug 2022 |
Application Filling date: 22 Apr 2022 Issue date: 18 Aug 2022 |
Application Filling date: 6 Jan 2022 Issue date: 18 Aug 2022 |
Application PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- -TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Filling date: 11 Apr 2022 Issue date: 11 Aug 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 26 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 2 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 27 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
Top 10 Income Funds From Eaton Vance
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
4 Reasons To Buy AbbVie
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data
LENZ Therapeutics: Presbyopia Eyedrops Look Promising
Dividend Yield Theory Says Merck Is A Buy
Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum
Merck: Don't Let Today's Bargain Opportunity Pass You By
-
What's the price of AbbVie stock today?
One share of AbbVie stock can currently be purchased for approximately $206.7.
-
When is AbbVie's next earnings date?
Unfortunately, AbbVie's (ABBV) next earnings date is currently unknown.
-
Does AbbVie pay dividends?
Yes, AbbVie pays dividends and its trailing 12-month yield is 3.48% with 213% payout ratio.It means that the company is paying a dividend greater than earnings. The last AbbVie stock dividend of $1.41 was paid on 15 Feb 2022.
-
How much money does AbbVie make?
AbbVie has a market capitalization of 309.79B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 6.44% to 54.32B US dollars.
-
What is AbbVie's stock symbol?
AbbVie Inc. is traded on the NYSE under the ticker symbol "ABBV".
-
What is AbbVie's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of AbbVie?
Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AbbVie's key executives?
AbbVie's management team includes the following people:
- Mr. Richard A. Gonzalez Chairman & Chief Executive Officer(age: 71, pay: $7,360,000)
- Dr. Michael E. Severino Vice Chairman & Pres(age: 59, pay: $4,290,000)
- Ms. Laura J. Schumacher Vice Chairman of External Affairs, Chief Legal Officer & Corporation Sec.(age: 62, pay: $4,200,000)
- Mr. Robert A. Michael Vice Chairman of Fin. & Commercial Operations and Chief Financial Officer(age: 55, pay: $3,220,000)
-
How many employees does AbbVie have?
As Jul 2024, AbbVie employs 50,000 workers.
-
When AbbVie went public?
AbbVie Inc. is publicly traded company for more then 12 years since IPO on 2 Jan 2013.
-
What is AbbVie's official website?
The official website for AbbVie is abbvie.com.
-
Where are AbbVie's headquarters?
AbbVie is headquartered at 1 North Waukegan Road, North Chicago, IL.
-
How can i contact AbbVie?
AbbVie's mailing address is 1 North Waukegan Road, North Chicago, IL and company can be reached via phone at +84 79327900.
-
What is AbbVie stock forecast & price target?
Based on 6 Wall Street analysts` predicted price targets for AbbVie in the last 12 months, the avarage price target is $211.29. The average price target represents a 2.22% change from the last price of $206.7.
AbbVie company profile:
AbbVie Inc.
abbvie.comExchange:
NYSE
Full time employees:
50,000
Industry:
Drug Manufacturers - General
Sector:
Healthcare
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
1 North Waukegan Road
North Chicago, IL 60064-6400
North Chicago, IL 60064-6400
CIK: 0001551152
ISIN: US00287Y1091
CUSIP: 00287Y109
